New weapons in the fight against cancer

The increase in our knowledge and understanding of molecular pathways is leading to the identification of novel and appealing targets in oncology. As such, new drug ‘weapons’ to target these are currently under evaluation and there has been an increase in the assessment of these novel agents at an early stage of clinical development. With molecular evidence accumulating at an exponential rate, there will be a surge in the development of targeted cancer preventions and interventions over the next decade. Some studies presented at this year’s ESMO Congress have provided a first glance at some new drugs that may improve cancer treatment in the coming years even further. Read more here.